SciSparc (SPRC) Net Income towards Common Stockholders (2016 - 2022)
SciSparc (SPRC) posted Net Income towards Common Stockholders of -$359000.0 for Q4 2022, down 113.14% sequentially from $2.7 million in Q3 2022.
SciSparc (SPRC) Net Income towards Common Stockholders (2016 - 2022) Analysis & Trends
SciSparc has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$359000.0 in Q4 2022.
- Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$359000.0 in Q4 2022, while the trailing twelve-month figure through Jun 2024 was -$359000.0 (down 115.13% YoY) and the FY2025 annual result came in at -$12.2 million, down 93.81% from the prior year.
- Net Income towards Common Stockholders slipped to -$359000.0 in Q4 2022 per SPRC's latest filing, from $2.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $2.7 million in Q3 2022 and troughed at -$12.3 million in Q4 2018.
- A 3-year average of -$438250.0 and a median of $1.2 million in 2018 frame the typical range for Net Income towards Common Stockholders.
- The widest YoY moves for Net Income towards Common Stockholders: up 222.01% in 2018, down 554.79% in 2018.
- Over 3 years, Net Income towards Common Stockholders stood at -$12.3 million in 2018, then surged by 101.6% to $197000.0 in 2019, then plunged by 282.23% to -$359000.0 in 2022.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$359000.0, $2.7 million, and $197000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | SciSparc | 831,418.60 | 831,418.60 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -359,000.00 |
| Sep 30, 2022 | 2.73 Mn |
| Jun 30, 2019 | 197,000.00 |
| Mar 31, 2019 | 1.85 Mn |
| Dec 31, 2018 | -12.33 Mn |
| Sep 30, 2018 | 1.14 Mn |
| Jun 30, 2018 | 1.21 Mn |
| Mar 31, 2018 | 2.05 Mn |
| Dec 31, 2017 | 2.71 Mn |
| Sep 30, 2017 | 1.03 Mn |
| Jun 30, 2017 | 1.86 Mn |
| Mar 31, 2017 | 636,000.00 |
| Dec 31, 2016 | 429,000.00 |
| Sep 30, 2016 | 536,000.00 |
| Jun 30, 2016 | 533,000.00 |